![<![CDATA[FDA Expands Approval for Arexvy for Adult Patients Aged 18-49 ]]>](https://theindustryexpert.com/wp-content/uploads/2026/03/41ae771ddeb14bb1df32ce13ba06cde733be25a5-1280x720-1.png)
![<![CDATA[Americans Cutback on Expenses to Cover Healthcare Costs: Report]]>](https://theindustryexpert.com/wp-content/uploads/2026/03/b2defa6b4904a34b5dfa8d86ebaaae1c7a81931b-1280x720-1.png)
Nuclear Facility Cyberattack Investigated as Possible Iranian Exploit
Poland’s National Centre for Nuclear Research defended against a cyberattack. Continue reading →
Discussing Use of Force in Security: A Challenging Discussion?
Some may consider the use of force in security to be a challenging discussion, but it must be had in order to improve functionally and ethically. Continue reading →
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
Lilly asked the FDA to step in after claiming that testing it’s done suggests copycat versions of Zepbound may carry “unknown risks.” Continue reading →
Cracking Cyber’s Talent Gap Challenge
Solving the cybersecurity workforce challenge requires a shift in perspective. Continue reading →
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure
Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA. Continue reading →
New FDA guidance could elevate pharma’s biosimilar market
Biologic copycats have had a limited impact on U.S. drug prices so far, but loosening regulatory restrictions could help accelerate their progress. Continue reading →
Families Scramble To Pay Five-Figure Bills as Clock Ticks on Promised Preauthorization Reforms
Sheldon Ekirch is used to being disappointed by her health insurance company. That’s why Ekirch, 31, of Henrico, Virginia, was stunned when she learned Anthem would finally have to pay for life-changing medical treatment. For two years, she had battled the company to cover blood plasma...